Scholarlink

<p>Prostate cancer (PCa), a globally prevalent male malignancy, necessitates breakthroughs in treating its hormone-refractory stage. The Traditional Chinese Medicine drug pair Hedyotis Diffusae Herba – Scutellaria Barbatae Herba (HDH–SBH) shows significant antitumor value, but its multi-component synergistic mechanisms remain unclear. This study elucidated HDH-SBH’s molecular mechanisms in suppressing PCa via apoptosis pathways. Network pharmacology predicted active components (quercetin, ursolic acid, apigenin) and core targets (AKT1, BCL2, NFKB) enriched in apoptosis (<i>P</i> &lt; 0.05). Molecular docking revealed strong binding (e.g., ursolic acid-AKT1: -7.76&#xa0;kcal/mol), confirmed by stable 100 ns molecular dynamics simulations (RMSD &lt; 5.0 Å). In vitro, HDH-SBH significantly inhibited PC-3 cell proliferation (48&#xa0;h IC<sub>50</sub> = 1.094&#xa0;mg/mL), reduced migration (36&#xa0;h rate decreased by 64.2%), and induced apoptosis (rate 13.57% vs. control 4.79%). It downregulated BCL2 and p-65 protein expression (<i>P</i> &lt; 0.05) while suppressing AKT1 phosphorylation. Thus, HDH-SBH targets the AKT1/BCL2/NFKB axis to regulate apoptosis and suppress PCa progression, providing a theoretical and experimental foundation for modernizing TCM in antitumor research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hedyotis diffusae herba -Scutellaria Barbata herba drug pair suppresses prostate cancer by inducing apoptosis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月17日

查看全文
  • Junfeng Qiu,
  • Litong Wu,
  • Zhiming Hong,
  • Yahong Shi,
  • Yi Wei,
  • Quan Wang,
  • Zilong Chen,
  • Weitian Chen,
  • Qing Zhang,
  • Xujun J. You,
  • Wenbin B. Zhou,
  • Wenban Zhou

摘要

Prostate cancer (PCa), a globally prevalent male malignancy, necessitates breakthroughs in treating its hormone-refractory stage. The Traditional Chinese Medicine drug pair Hedyotis Diffusae Herba – Scutellaria Barbatae Herba (HDH–SBH) shows significant antitumor value, but its multi-component synergistic mechanisms remain unclear. This study elucidated HDH-SBH’s molecular mechanisms in suppressing PCa via apoptosis pathways. Network pharmacology predicted active components (quercetin, ursolic acid, apigenin) and core targets (AKT1, BCL2, NFKB) enriched in apoptosis (P < 0.05). Molecular docking revealed strong binding (e.g., ursolic acid-AKT1: -7.76 kcal/mol), confirmed by stable 100 ns molecular dynamics simulations (RMSD < 5.0 Å). In vitro, HDH-SBH significantly inhibited PC-3 cell proliferation (48 h IC50 = 1.094 mg/mL), reduced migration (36 h rate decreased by 64.2%), and induced apoptosis (rate 13.57% vs. control 4.79%). It downregulated BCL2 and p-65 protein expression (P < 0.05) while suppressing AKT1 phosphorylation. Thus, HDH-SBH targets the AKT1/BCL2/NFKB axis to regulate apoptosis and suppress PCa progression, providing a theoretical and experimental foundation for modernizing TCM in antitumor research.